share_log

Citigroup Maintains Neutral on Galera Therapeutics, Lowers Price Target to $0.25

Benzinga ·  Aug 29, 2023 12:34

Citigroup analyst Yigal Nochomovitz maintains Galera Therapeutics (NASDAQ:GRTX) with a Neutral and lowers the price target from $0.4 to $0.25.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment